Why Vaxart Stock Tumbled in September

Shares of the developmental-stage biotech Vaxart (NASDAQ: VXRT) sank by 11.5% last month, according to data provided by S&P Global Market Intelligence. The biotech's stock has been sliding hard over the past month and half for two related reasons:

Image source: Getty Images.

Vaxart's shares were once up by over 300% not so long ago. The biotech's stock has since given back the vast majority of these gains, especially over the past six weeks. Not all of these issues have been Vaxart's fault, however.

Continue reading

Source Fool.com